IVIEW Therapeutics announced today that its innovative gene therapy candidate GVB-2001 has successfully completed treatment of the first patient with primary open-angle glaucoma (POAG), marking a key clinical milestone and opening a new chapter for glaucoma management unconstrained by patient-specific genetic backgrounds. The procedure was performed under the direction of…
Read More
Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM),…
Read More
Strategic Co-Development Partnership Expands Relationship between Bon Secours Mercy Health and Atalan to Unify Workforce and Patient Experience Analytics PHILADELPHIA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Atalan, the world’s first Clinical Retention Intelligence (CRI) platform, today announced a strategic partnership with Accrete Health Partners, the venture arm of Bon Secours…
Read More
IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Houston, Texas, Dec. 4, 2025 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that the company has been awarded…
Read More
LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 disease FDA designations underscore the potential of LTS-101 to address a high unmet medical need PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company…
Read More
IVIEW Therapeutics (“IVIEW”) today announced that its investigational ophthalmic drug, IVIEW-1201D, has received U.S. Food and Drug Administration (FDA) Phase III IND clearance for the treatment of adenoviral conjunctivitis. This important milestone marks the program’s entry into a new phase of global, pivotal clinical development and represents a major step…
Read More
PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will share interim clinical data from its Phase 1 first-in-human study of VIPER-101, a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory (r/r) T-cell lymphoma (TCL), in…
Read More
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning (AI/ML) strategy and the addition of two world-class scientific advisors: Pranam Chatterjee, PhD (University of Pennsylvania) and Philip M. Kim, PhD (University…
Read More
The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients. The ongoing pilot study in cooperation with DEBRA Chile has enrolled 18 patients to date, with no drug-related side effects observed among the first 8 participants who have completed treatment.…
Read More
Patient-specific human immune system-bearing mouse model created by implanting human thymic cells derived from iPSC with Tolerance Bio’s proprietary process Human T cells educated in vivo by thymic organoids delayed melanoma tumor growth in a patient derived xenograft model Data support the development of Tolerance Bio’s thymic cells and pharmacological…
Read More
Healthcare is transforming rapidly, driven by technological advancements, evolving patient expectations and shifting demographics. While these changes propel our industry forward, significant gaps in access continue. As we enter this new era, it is critical that we partner with clinicians across the industry to constantly explore new ways to optimize.…
Read More
Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Allschwil, Switzerland, September 25, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections,…
Read More
Healthcare is entering a new era filled with opportunity. Hospitals are exploring smarter ways to care for patients with the staff they have. Pharmaceutical companies are rethinking how to bring therapies to market with greater speed and precision. Across the industry, one theme is clear: AI-powered automation and data are…
Read More
The National Heart, Lung and Blood Institute (NHLBI) of the U.S. National Institutes of Health (NIH) has awarded VESTECK Inc. a Direct to Phase II SBIR Grant to support the pre-market development and clinical validation of the Suture-Tight™ Endovascular Suturing device (Award Number R44HL178318). This grant, totaling $1.98M, is broken…
Read More
SEATTLE--(BUSINESS WIRE) --Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected KAYO-1732 as a drug development candidate. KAYO-1732 is a novel, orally-available, small molecule inhibitor of the Aldehyde dehydrogenase 1A3 (ALDH1A3) enzyme, developed for the…
Read More
Atalan is Pioneering the Clinician Retention Intelligence (CRI) Category in Healthcare Healthcare systems thrive when clinicians do. Atalan, a healthcare workforce technology company, is leading the way in helping hospitals and health systems protect revenue, retain clinicians, and sustain high-quality patient care. With over 60% of physicians and nearly half…
Read More
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics September 8, 2025 10:30 AM, PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, and…
Read More
Strados Labs Collaborates with Rutgers Robert Wood Johnson Medical School, RWJBarnabas Health to Evaluate Wearable Respiratory Monitoring Cystic Fibrosis The pilot study explores the RESP® Biosensor’s potential to allow for low-effort home monitoring in patients with acute and chronic cystic fibrosis. by Strados Labs | Aug 28, 2025 | Press Releases Philadelphia,…
Read More
IVIEW Therapeutics is pleased to announce the appointment of Jeanette Stewart, RN, as the Director of Clinical Operations Bringing more than 30 years of expertise in ophthalmic clinical research, Ms. Stewart is a seasoned professional who has successfully managed clinical trials across all stages of development. She is the CEO…
Read More
First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease IVIEW Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating IVW-1001, a novel topical therapy for dry eye disease. The initial dosing was conducted at the Eye Research…
Read More